Yuexiu REIT Wins the Best ESG (Social) Award at 9th Investor Relations Awards

HONG KONG, Jun 30, 2023 – (ACN Newswire) – Yuexiu Real Estate Investment Trust ("Yuexiu REIT", together with Yuexiu REIT Asset Management Limited, stock code: 405. HK) received the "Best ESG (Social) Award" for its outstanding social responsibility performance at the 9th Hong Kong Investor Relations Awards (the "Awards") organized by the Hong Kong Investor Relations Association (HKIRA), speaking volumes to the high recognition it enjoys for its ESG efforts in the investment community.



The Awards this year with 15 categories, attracted 126 well-known Hong Kong-listed companies to participate and 41 of them won awards. The winners were selected after two rounds of voting, which took place between March 21 and April 27, by more than 740 qualified voters, including buy-side and sell-side analysts and fund managers, and over 290 professional financial institutions-together with Link REIT, Fortune REIT, Sunlight REIT, SF REIT and Champion REIT won awards at the ceremony, Yuexiu REIT won the "Best ESG (Social) Award", recognizing and affirming its ESG endeavors.

For seven years since 2016, Yuexiu REIT has released its "Environmental, Social and Governance Report", and at the same time, it has continued to promote the organic integration of ESG concepts into its business models. Heeding the diverse scenarios involving business partners, employees, merchants and the public, Yuexiu REIT has built a green development ecology and led the ESG innovation trend in the commercial real estate sector. In 2022, Yuexiu REIT's outstanding ESG performance was recognized and recommended to investors by many rating agencies, with its MSCI ESG rating upgraded to "BB", GRESB rating upgraded to "Green Four-Star", and it scoring "A" grade for public disclosure (the highest of disclosure standard) for two consecutive years, and its first "Low Risk" ESG rating from Sustainalytics, which is also the "Highest ESG Rating for Asia-Pacific Area in 2023". In addition, its green and sustainable debt financing amount reached record high. As at the end of 2022, the proportion of green and sustainable-related debts of the REIT was 38.5%, and it will keep optimizing green and sustainable debt financing.

Regarding corporate social responsibility, the REIT is committed to creating the greatest value for employees, customers and the society, and adhering to the concept of sustainable development in promoting continuous social progress. The "YEService" system is implemented across all its properties to ensure customers are provided with services that are comfortable, safe and efficient, and caring. In addition to supporting community development, Yuexiu REIT fosters public well-being by making donations of materials, buying produce from farmers to support their livelihood and agriculture. It also pools resources by collaborating with neighborhoods, communities and volunteer groups and takes full advantage of its influence to hold for charity exhibitions and interactive activities, such as markets for munificent causes, concerts, theme salons, to encourage more people to pay attention to and partake in charitable activities.

As a real estate investment trust focusing on the Chinese mainland and Hong Kong markets, Yuexiu REIT sees strategic importance in building ESG capacity and regards it as a key handhold for enhancing core competitiveness. The award win has led Yuexiu REIT to believe that the integration of commercial real estate and ESG has become an important way to enhance the value of assets from the perspectives of green buildings, energy conservation and carbon reduction, service improvement, and risk prevention. Yuexiu REIT will continue to focus on taking its sustainable development strategies to greater depth and put ESG concepts into practice, and together with investors create a sustainable future. Besides, Yuexiu REIT stays connected to communities and provide venues for all kinds of charity activities, and continuously strengthen the goal of social welfare from volunteer team building.

About Hong Kong Investor Relations Association (HKIRA)
Founded in 2008, Hong Kong Investor Relations Association is a non-profit professional association comprising investor relations practitioners and corporate executives, with the aim of fostering communication between corporate management and the investment community. Most of its members work in companies listed on the Hong Kong Stock Exchange. Among Hang Seng Index constituent stocks,64% are members of the association. The HKIRA Investor Relations Awards (the "IR Awards"), which was established by the association in 2015, is well-recognized by the Hong Kong investment community for its professional, rigorous and fair selection system and high credibility. Candidates have to be nominated by the public, then voted on by professionals including qualified domestic and foreign fund managers, securities analysts. Its aim is to honor and reward individuals and companies for their high-standard investor relations work, making them worthy role models to the investment community.

About Yuexiu Real Estate Investment Trust
Yuexiu Real Estate Investment Trust ("Yuexiu REIT") was listed on the Hong Kong Stock Exchange of Hong Kong Limited on 21 December 2005 and is the first listed real estate investment trust only investing in properties in the People's Republic of China (the "PRC") in the world. The current property portfolio comprises ten high quality properties, namely Guangzhou International Finance Center, White Horse Building, Fortune Plaza, City Development Plaza, Victory Plaza, Yuexiu Financial Tower in Guangzhou, Yuexiu Tower in Shanghai, Wuhan Properties in Wuhan (including Wuhan Yuexiu Fortune Centre and Starry Victoria Shopping Centre), Victory Business Centre in Hangzhou and Yuexiu Building in Hong Kong, with a total area of ownership of approximately 1.184 million sq.m. All properties are located in the central business district of Guangzhou, Shanghai, Wuhan, Hangzhou and Hong Kong respectively. The categories of the properties include Grade-A offices, commercial complexes, retail business, hotel, serviced apartments and professional clothing market etc.

For media enquiries:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834
Holly Szeto Tel: (852) 2864 4859
Lilia Yang Tel: (852) 2864 4833
Website: http://www.sprg.com.hk
Email: sprg_yx@sprg.com.hk


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Tat Hong Equipment Service Co., Ltd. Announces 2022/23 Annual Results

HONG KONG, Jun 29, 2023 – (ACN Newswire) – Tat Hong Equipment Service Co., Ltd. ("Tat Hong" or the "Company", together with its subsidiaries, the "Group") (Stock Code: 2153), the first foreign-owned tower crane service provider established in the PRC, has announced its annual results for the year ended 31 March 2023 ("FY2023" or the "Year").

In FY2023, the Group recorded revenue of approximately RMB770.8 million, representing a decrease of RMB96.3 million or 11.1% from the year ended 31 March 2022. Loss attributable to equity holders of the Company for the Year amounted to RMB35.8 million, as compared with a profit attributable to equity holders of the Company of approximately RMB47.6 million for the year ended 31 March 2022. This was primarily due to (i) the dramatic increase of exchange loss of approximately RMB37.2 million arising from foreign currency loans and other exchange risk; and (ii) the decrease in revenue due to the outbreak of COVID-19 and the corresponding control measures particularly in Eastern China, which resulted in the delay and postponement of some projects thereby affected the Group's revenue. Our average monthly service price of tower cranes per tonne metres (TM) in use decreased from RMB279.0 to RMB241.0. The overall gross profit and gross profit margin decreased to RMB173.2 million and 22.5%, respectively.

The Group's total tonne Metres (TM) in use increased from 3,112,084 for the year ended 31 March 2022 to 3,192,710 for the year ended 31 March 2023. As at 31 March 2023, the Group had 281 projects in progress with a total outstanding contract value of approximately RMB566.7million and 44 projects on hand with a total expected contract value of approximately RMB 114.5 million. Of these projects, the Group expects to complete approximately RMB 544.6 million worth of contract work by the end of 31 March 2024, demonstrating solid earnings visibility.

While the PRC market was adversely affected by the COVID-19 outbreak and subsequent pandemic containment measures throughout 2022, the Group proactively optimized its operation and management. The Group's subsidiaries expanded their digital management with the self-developed software "TOP" and "iSmartCon", which improved the efficiency of management and operations. The Group has continued to refine and adjust internal processes to further enhance its business operations. At the same time, the Group strove to seek quality projects and actively pursued business contracts in the clean energy, infrastructure and public construction sectors, especially in delivering services with large-scale tower cranes, so as to improve its business and financial performance in the next reporting period.

Mr. Sean Yau, CEO of Tat Hong Equipment Service Co., Ltd. said, "Against the backdrop of economic recovery and the introduction of favourable policies in the region, China's infrastructure investment and real estate markets are gradually picking up. Together with the 'Outline of the 14th Five-Year Plan and 2035 Long-range Objectives' and the national development goals such as 'expanding domestic demand, accelerating the construction of a modern industrial system and promoting a green transformation of development methods' mentioned at the 'Two Sessions', it is believed that a number of major infrastructure projects will be launched, including traditional infrastructure, new infrastructure and energy projects, which will provide the Group with tremendous business development opportunities. At the same time, given the development opportunities in the Greater Bay Area, the Group has adjusted its internal structure and incorporated two new companies in the South to respond to the opportunities in the area."

Mr. Roland Ng, Chairman of Tat Hong Equipment Service Co., Ltd. concluded, "With the pandemic subsiding and work and production resuming smoothly, the PRC has launched a series of industry subsidy policies and programs to promote economic development. We have entered the post-pandemic era, where both opportunities and challenges exist. Looking ahead, the Group will continue to be guided by the core values of 'Virtue, Safety
and Excellence", and will further improve and focus on the Group's strategic goals for sustainable development. By improving digital management across the Group, we can share resources, reduce costs and improve efficiency, while aggressively pursuing international business. This series of measures can also improve operating efficiency and achieve the Group's goal of becoming the 'best construction equipment service provider'."

About Tat Hong Equipment Service Co., Ltd. (Stock Code: 2153)
Tat Hong Equipment Service Co., Ltd. is the first foreign-owned tower crane service provider established in the PRC. Since 2007, the Group has established as a tower crane service provider for one-stop tower crane solution services from consultation, technical design, commissioning, construction to after-sales services primarily to Chinese Special-tier and Tier-1 EPC contractors. Guided by its core values, "Virtue, Safety and Excellence", the Group has successfully established its market position and maintained stable, reputable and loyal customer base in the construction industry in the PRC.

Media Enquiries
Strategic Financial Relations Limited
Heidi So Tel: (852) 2864 4826 Email: heidi.so@sprg.com.hk
Mel Lai Tel: (852) 2864 4855 Email: mel.lai@sprg.com.hk


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

AEON Credit Revenue Jumps 36.2% to HK$380.0 Million in First Quarter of 2023/24, Profit Increases by 17.3% to HK$97.0 Million

HONG KONG, Jun 29, 2023 – (ACN Newswire) – AEON Credit Service (Asia) Company Limited ("AEON Credit" or the "Group"; Stock Code: 00900) today announced its results for the three months ended 31 May 2023 ("Q12023" or the "Reporting Period").

In Q12023, the Group's revenue climbed by 36.2% year-on-year to HK$380.0 million, and operating profit before impairment losses and impairment allowances surged by 39.4% to HK$177.0 million. Meanwhile, profit after tax was up 17.3% to HK$97.0 million, with earnings per share increasing to 23.16 HK cents (Q12022: 19.74 HK cents).

During the Reporting Period, the Group continued to use targeted marketing and successful marketing promotions to boost sales and receivables growth momentum, with overall sales increasing by 39.4% compared with the first quarter of last year ("1Q2022", or the "Previous Period"), and the gross advances and receivables balance up by 5.5% from the end of February 2023. With the continued increase in the revolving credit card receivables and personal loan receivables balances, together with the increase in interest rates on card credit purchases, the Group recorded a 35.8% or HK$83.7 million rise in interest income year-on-year, and accordingly a notable growth in the Group's overall revenue. Handling and late charges meanwhile also recorded a significant rise of HK$14.3 million in the Reporting Period as a result of higher demand for cash advances and increase in customers making minimum due payments. Besides, the Group recorded an increase of HK$2.9 million in fees and commissions, largely driven by the card acquiring business that has undergone significant expansion in terms of merchant network and transaction size.

Among its business development initiatives, the Group's new card and loan system project, AEON Netmember service and "AEON HK" Mobile App with enhanced cybersecurity protection were successfully rolled out in early March 2023 to accelerate digital transformation. The project facilities more flexible creation and delivery of new payment solutions and product benefits, as well as easy access to better data analytics tools and services in the near future. The Group has also continued to revamp and expand its branch network to meet a growing demand for face-to-face advisory services from customers.

Looking forward, with strong government support to boost post-Pandemic recovery, economic activity in Hong Kong is expected to continue to rebound in the second quarter of 2023/24. Following successful marketing and brand building efforts, the Group will place greater emphasis on making the best use of both digital and traditional marketing channels to promote its credit card and personal loan products and to roll out unique mass marketing programs to enrich the customer experience and capture increasing demand of consumer finance products.

In terms of technology development, the Group will deploy the new card and loan system for enhancing its digital marketing and offering new payment solutions to its customers. In addition, data analytics tools are ready to further help improve the effectiveness of the Group's marketing, credit assessment and credit management activities.

For the Mainland China businesses, the microfinance subsidiary in Shenzhen will continue to focus on exploring business opportunities in the Greater Bay Area to grow its receivables with sound asset quality and abundant financial resources.

Mr. Tomoharu Fukayama, Managing Director of AEON Credit, said, "The strong first quarter performance demonstrates our capabilities in capturing opportunities from the recovering market. With a strong capital position, we will continue to devote resources to enhancing our branch services, providing higher quality customer experiences, accelerating digitalization and exploring new investment opportunities to expand and diversify our businesses. We look forward to continuing to deliver strong results and creating greater value for all our stakeholders."

About AEON Credit Service (Asia) Company Limited (Stock Code: 00900)
AEON Credit Service (Asia) Company Limited, a subsidiary of AEON Financial Service Co., Ltd. (TSE: 8570) and a member of the AEON Group, was set up in 1987 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 1995. The Group is principally engaged in the consumer finance business, which includes the issuance of credit cards and the provision of personal loan financing, card payment processing services, insurance agency and brokerage business in Hong Kong and microfinance business in Mainland China.

For more information, please visit the company's website at www.aeon.com.hk.


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Regina Miracle Records Revenue of HK$7.88 Billion and Adjusted Net Profit of HK$460 Million for Fiscal 2023, Recommends Total Dividend of HK 10.3 Cents, Distributing No Less than 30% of Net Profit

HONG KONG, Jun 29, 2023 – (ACN Newswire) – Regina Miracle International (Holdings) Limited ("Regina Miracle" or the "Company", together with its subsidiaries, the "Group") (HKEX: 2199), a leading global intimate wear company boasting an innovative design manufacturer ("IDM") business model, has announce its annual results for the year ended 31 March 2023 ("the year under review" or "Fiscal 2023").

During the year under review, the threat from the global pandemic receded, thereby facilitating the resumption of trade and logistics, as well as the development of diversified consumption scenarios. As a result, the Group achieved the best business performance in its history in the first half of Fiscal 2023. Nevertheless, the impact of global economic uncertainty led to greater volatility in the latter half of the year under review. Between the wax and wane of the first and second halves of the year under review, the Group recorded revenue of approximately HK$7,879.3 million (Fiscal 2022: HK$8,346.7 million), representing a year-on-year decrease of 5.6%. Gross profit decreased by 7.0% to approximately HK$1,902.1 million, with gross profit margin decreasing by 0.4 percentage points to 24.1% (Fiscal 2022: HK$2,045.4 million and 24.5%, respectively). Earnings before interest, taxes, depreciation and amortization (EBITDA) decreased by 1.8% to approximately HK$1,310.0 million, with EBITDA margin increasing by 0.6 percentage points to 16.6% (Fiscal 2022: HK$1,333.8 million and 16.0%, respectively). The Group recorded a net profit of approximately HK$383.3 million for the year under review, representing a year-on-year decrease of 26.4%, with net profit margin decreasing by 1.3 percentage points to 4.9% (Fiscal 2022: HK$520.7 million and 6.2%, respectively). Basic earnings per share attributable to owners of the Company was HK31.3 cents (Fiscal 2022: basic earnings per share of HK42.5 cents). Excluding one-off expense items, adjusted EBITDA decreased by 0.2% to approximately HK$1,385.4 million, and adjusted EBITDA margin increased by 1.0 percentage point to 17.6% (Fiscal 2022: HK$1,388.8 million and 16.6%, respectively). Adjusted net profit was approximately HK$458.7 million for the period, representing a year-on-year decrease of 20.3%, with adjusted net profit margin decreasing by 1.1 percentage points to 5.8% (Fiscal 2022: HK$575.6 million and 6.9%, respectively).

During the year under review, the Group's financial position was sound, with net current assets increasing to approximately HK$1,585.6 million (Fiscal 2022: HK$1,519.4 million). As at 31 March 2023, its total undrawn banking facilities amounted to approximately HK$3,783.6 million (31 March 2022: approximately HK$2,371.0 million). In order to share these fruitful results with shareholders, the Board has resolved to recommend a final dividend of HK1.8 cents per share for Fiscal 2023 (Fiscal 2022: HK7.2 cents per share), which together with the interim dividend of HK8.5 cents per share, makes a total dividend of HK10.3 cents, in line with the Group's dividend policy of distributing no less than 30% of its net profit for the financial year.

Mr. YY Hung, Chairman, Chief Executive Officer & Executive Director of Regina Miracle, said, "As industry consolidation looms and mainstream markets undergo a destocking cycle, we recognize that striking a balance between risk and development is the key principle in surmounting current industry challenges. We have therefore continued to strengthen our competitive barriers across multiple dimensions focusing on 'innovation, speed, quality and sustainability'. We have also maintained acuity in responding to market changes and have joined hands with partners to achieve breakthroughs. Meanwhile, the Group has been actively developing the thriving PRC market, and the establishment of a joint venture ('VS China') between the Group and Victoria's Secret & Co. ('Victoria's Secret') is one of our key initiatives. By leveraging our IDM capabilities and in-depth understanding of Chinese consumers, as well as the brand recognition of Victoria's Secret, we have initially established a profitable business model that will generate tremendous synergies with our existing IDM business in the PRC market, creating a medium to long-term growth engine for the Group. By adhering to an IDM business model over the years, Regina Miracle has been able to navigate through various macroeconomic and development cycles. Our commitment to innovation has allowed us to expand our business both vertically and horizontally, enabling us to collaborate with our partners and establish a leading position in the industry. Although the second half of the fiscal year presented numerous challenges to the operating environment due to macro factors, the Group was able to withstand the market changes and maintain steady business development by leveraging our leading innovative research and development capabilities, solid strategic partnerships with brand partners, and the multiple advantages of scale, stability and flexibility of our Vietnam production base."

BUSINESS REVIEW

The Overall Performance of Intimate Wear Segment Remains Stable, Product Value Enhanced through Leading R&D Capabilities and Innovative Technologies
During the year under review, this business segment contributed revenue of approximately HK$4,424.8 million (Fiscal 2022: HK$4,716.0 million), a year-on-year decrease of 6.2% and accounting for 56.2% of the total revenue, and remained the Group's main source of revenue. The segment's gross profit decreased by 6.8% to approximately HK$1,108.4 million, with gross profit margin decreasing by 0.1 percentage points to 25.1% (Fiscal 2022: HK$1,189.2 million and 25.2%, respectively). The weakened global economy further dampened consumer sentiment, and intimate wear, being part of the general consumer goods, was inevitably impacted. Despite the sales from major brand partners in the US market recorded relatively significant declines, the overall performance of intimate wear business remained stable thanks to the stable growth of major brand partner in the Japanese market as well as the new contributions of sales from VS China. However, drawing on its industry-leading R&D capabilities and innovative craftsmanship, the Group continued to implement its strategies of differentiation and sub-category expansion, while putting effective product quality management in place, thereby striving to create excellent product value through continuous innovation and quality improvement, as well as consolidating its partnerships with existing brand partners.

Sports Products Segment Remains Resilient with Revenue up over 10% year-on-year and a Diversified Product Matrix Resulting in High Development Prospects
This business segment contributed revenue of approximately HK$2,436.3 million during the year under review (Fiscal 2022: HK$2,190.7 million), representing a year-on-year increase of 11.2% and accounting for 30.9% of total revenue. The segment's gross profit was approximately HK$566.5 million and gross profit margin was 23.3% (Fiscal 2022: HK$513.9 million and 23.5%, respectively). Sales of sport bras remained stable during the year under review, while sports leggings and sportswear were the main growth drivers for this business segment. The Group's solid brand partnerships supported growth in different categories amid short-term business fluctuations as the three leading core technologies accelerated the R&D of new products. Meanwhile, sports leggings maintained strong growth momentum thanks to a diversified brand partners base and product matrix.

Digital and Intelligent Production to Reduce Costs and Increase Efficiency, with a Multi-Regional Footprint to Respond Flexibly to Market Changes
To respond rapidly to the demand from its domestic and international brand partners, the Group is committed to enhancing its production capacity, reducing costs and improving efficiency, thereby achieving explosive power of the production capability and economies of scale. The Group continued to optimize its production processes through four key initiatives, including manufacturing automation, management digitalization, improvement on its staff's efficiency and supply chain localization, to improve production efficiency and product quality, while enhancing employee's skills and reducing costs. The Group's longstanding collaboration and continued rapport with its brand partners are instrumental in enhancing production efficiency and ultimately increasing gross profit margins. Furthermore, the localization of its supply chain is conducive to further shortening response time.

Vietnam accounted for 85% of the Group's total revenue as of 31 March 2023 as it has played an increasingly important role as the main production base for Regina Miracle. In response to the decline in export orders in the second half of Fiscal 2023, the Group has temporarily suspended local recruitment in Vietnam since last September and made appropriate optimization of its local workforce structure, reducing the number of employees from a peak of more than 39,000 last year to approximately 31,600. It also adjusted production units and operating hours to promote workforce utilization rate. In addition, the Group has further implemented localization of personnel, with local employees accounting for 98% of the workforce. Meanwhile, in Mainland China, the Shenzhen production base employed approximately 5,100 staff members. Furthermore, construction of the first phase of the Group's production base in the Zhaoqing New District Industrial Park is well underway as planned, and will commence operations and production in phases in the current fiscal year. It is expected to create effective synergy and collaboration with the Shenzhen production base.

VS China Joint Venture Sees Rapid Growth in the PRC and Records Profit in its First Quarter, Maintains Positive Momentum to Support a Virtuous Cycle
Benefiting from Regina Miracle's customized supply-side and product-side mechanisms for e-commerce consumption scenarios, VS China has been able to fully capture the opportunity presented by the booming e-commerce channel just one year after [its completion/establishment], and has significantly improved its operating performance and further restored its profitability. Its operating revenue amounting to HK$1,344.2 million in Fiscal 2023 of the Group (2022/4-2023/3). In particular, profitability started to achieve significant improvement in the second half of the year, turning around a loss to profitability.

The Group has made notable progress in its integration with the VS China team. The differentiated products jointly developed by the two parties swiftly entered the market and opened up prospects by leveraging the e-commerce channel that was the focus of development and has seen rapid growth in the past year. In addition, integrated and seamless communication, as well as the agile supply mechanism, have effectively amplified the unique advantages of the e-commerce channel. As a result, the synergies created have reinvigorated VS China's growth. The Group is confident of driving VS China's continued growth and profitability in the future through the dual channels of e-commerce platforms and offline stores, and utilizing it to drive the growth of relevant IDM business between the Group and VS China, acting as a growth engine for purchase orders.

WHILE DESTOCKING OF BRAND PARTNERS CONTINUES, REGINA MIRACLE's DIVERSIFICATION STRATEGY OF "PRODUCTION BASE, END-MARKET, PRODUCT CATEGORY" REMAINS INTACT TO DRIVE POSSIBLE PERIOD-ON-PERIOD IMPROVEMENT IN OVERALL BUSINESS PERFORMANCE

As it enters Fiscal 2024, the Group expects the factors that suppressed order demand in the previous fiscal year, such as high inflation and brand partners' inventory pressure, to gradually ease, which will drive a slight period-on-period improvement in revenue in the first half of the year and a further return to year-on-year and period-on-period growth in the second half of the year. Continued strong demand for innovative products in the United States and Europe markets, coupled with ongoing supply chain concentration by brand partners and thus their strengthened strategic partnerships with industry-leading supply chain companies with outstanding R&D capabilities, will also provide strong support for the Group's recovery from the downturn in the second half of Fiscal 2023.

Consolidate Human Resources and Strengthen Efficiency and Competitiveness through Continued Investment in Digitalization amidst Industry Cycle
While focusing on craftsmanship advancement, Regina Miracle has always been committed to innovation in production models and equipment, continuously improving automation levels and significantly reducing the use of labor in production process. These have opened up a wide room for improving productivity and flexibility. The Group will continue to reduce manual intervention and thus costs while increasing efficiency per employee through digitalized data management, production craftsmanship templating, streamlined production processes and automation of production operations. Based on the results of current internal efficiency enhancements, if the sales volumes return to the peak level seen in the first half of Fiscal 2023, the Group expects to maintain the same level of production scale with approximately 20% less manpower, reflecting the effectiveness in its production efficiency improvements and competitiveness. The cost structure can then be further optimized and the gross profit margin is expected to improve. The Group has also developed a five-year digitalization roadmap with clear implementation targets to maintain and strengthen collaboration and integration with its strategic brand partners in the field of digitalization.

Drive the Expansion of Products from Intimate Wear to Outerwear Riding on the Three Core Technologies
Over the years, the Group has adhered to the IDM business model based on three core technologies and developed a series of diversified technology matrix. Among them, the latest diversified seamless bonding technology enjoys a leading advantage in the market, opening up a novel and unique development path that is different from the traditional sewing processes. The Group will continue to strengthen the promotion of this new technology among existing and new brand partners, striving to gradually expand its application scope from intimate wear to outerwear, further enriching the Group's product portfolio and expanding into a broader market. For example, in pursuit of better economies of scale in production, the Group has taken the initiative to terminate its cooperation with its existing footwear brand partner. With regard to the production space and capacities released by this termination, the Group will strategically redeploy them to the seamless bonding apparel business. The Group is confident that this category will add momentum to our business performance.

Regina Miracle's own leading position in the intimate wear segment and further success in different products such as sports bras and sports leggings show that its core technological craftsmanship can be effectively applied to a wide range of scenarios, support a variety of functions and meet the positioning and needs of different brand partners. This will help replicate one product's success to different fields, thereby creating a sustainable and efficient growth trajectory in the long run.

Leverage VS China to Expand Market Share in China and Diversify Income Streams Geographically
As part of its strategic deployment to expand market share in China, the Group's joint venture VS China has initially established a profitable business model since the launch of its joint venture VS China last year by leveraging its IDM capabilities and its understanding of Chinese consumers, coupled with the brand recognition of Victoria's Secret in the market and a series of strategic measures such as operation optimization and product differentiation. The gradual recovery of the overall retail market in China since this year drove the gradual restoration of offline channel business, and the rapid growth of VS China's online business have given a tremendous boost to its overall profit improvement. VS China has achieved profit from in the joint venture in the first quarter of Fiscal 2024, and with the implementation of more initiatives to improve business performance, profits are expected to increase further in the next fiscal year. Meanwhile, the business growth of VS China also drives the corresponding IDM business of the Group, which becomes a medium to long-term continuous growth engine for the Group.

In addition, the Group has gained a better grasp of domestic market trends and will continue to optimize the process to build a more adaptable and flexible supply chain mechanism, take advantage of the industry reshuffling cycle to gain shares of cooperation with domestic brands and expand revenue from the Chinese market.

Relocation of Zhaoqing Base Well Underway to Create Synergy with Shenzhen Base
In accordance with the plan to optimize the production layout in China, the Group will relocate its domestic production base to the Zhaoqing New District Industrial Park in the Greater Bay Area, and will complete the first phase of relocation, which involves the production of consumer electronics components, in August this year. In the next two years, apart from retaining the essential functions of the Shenzhen factories, the relocation of other related production units will be completed in phases to ensure a smooth transition of production capacity. The relocation plan will incur a one-off seniority compensation for employees, which will be paid by the Group in phases as the relocation progresses.

The new production base in Zhaoqing has highly automated and digital production facilities, which will greatly improve the overall production efficiency. With the expanded scale, the Group can better support the huge local production demand for the fast-growing domestic business, and shorten the lead time to shorten the lead time to fulfill speed orders. This will facilitate the cooperation with international brand partners in their strategy to develop the PRC market and attract more quality domestic brand partners.

Fulfillment of Corporate Responsibility and Extensive Recognition for the Continuous ESG Efforts
Recognizing the importance of environmental, social and governance ("ESG"), Regina Miracle has set clear sustainable development goals under the "2030 Sustainable Development Agenda" in the four areas of carbon reduction, waste management, sustainable innovation, and people and community. The Group's investment in ESG has been widely recognized. Mr. YY Hung, the Group's Chairman, Chief Executive Officer and Executive Director, was named by Forbes China as one of the "2023 Greater Bay Area Best 30 ESG Entrepreneurs", demonstrating the outstanding performance of the Group and Mr. Hung in terms of "corporate leadership", "industry foresight", "innovation" and "personal influence". In addition, the Group received five awards – the "Best IR Company", "Grand ESG Award (Small Cap)", "Best ESG (E)", "Best ESG (S)" and "Best ESG (G)" from the Hong Kong Investor Relations Association this year. What's more, the Group was once again named as one of the "Top 100 Sustainable Business in Vietnam", and also received the "Women's Empowerment Principles" award from UN Women and the Vietnam Association of Women Entrepreneurs in 2022 and the third prize in the "Gender Equality in the Workplace" program. Going forward, the Group will continue to integrate environmental and social responsibility into management decisions, daily operations and corporate culture to promote comprehensive sustainable development and create long-term value for all stakeholders.

Mr. Hung concluded: "Despite the challenges we have faced over the last fiscal year, Regina Miracle managed to make steady progress by adhering to the IDM business model and staying agile. In light of the present circumstances, we are aware that some of our brand partners are making progress in destocking in their overseas market deployment. Therefore, we are actively seizing the opportunities arising from the supply chain consolidation of core customers, while coordinating the front-end marketing and back- end production of "VS China + Domestic Base" to firmly expand our market share in the PRC, thereby gaining a broader scope for development. At the same time, we are committed to further expanding our product categories based on our three core technologies to offer a wider range of products and consolidate our leading market position. We will continue to monitor industry trends and optimize our business model and capacity allocation strategies according to market demand. Furthermore, we will strengthen communication and cooperation with all partners in the supply chain and leverage our close working relationships with them to navigate future challenges and opportunities, and take the lead to drive industry transformation. With our strategies adapted to industry trends, we anticipate that Regina Miracle's business essentially bottomed out in the fourth quarter of the current fiscal year and is expected to bring business growth momentum in the first and second quarters of the new fiscal year, achieving half-on-half improvement for the first six months. We will maintain the spirit of openness, innovation, cooperation and win-win, strengthen internal management and external cooperation, enhance our strength and competitiveness, striving for business recovery, while making comprehensive preparations for better future development. Last but not least, I would like to express my sincere appreciation to all colleagues for their hard work and dedication, and our brand partners and supply chain partners as well as investors for their tremendous support and enduring trust, which have enabled Regina Miracle to bring a diverse cross-category product offering to our brand partners and consumers and create long-term value for shareholders and stakeholders."

About Regina Miracle International (Holdings) Limited
Founded in Hong Kong in 1998, Regina Miracle International (Holdings) Limited is a global leader in the intimate wear manufacturing industry. By adopting an innovative design manufacturer ("IDM") business model and building on a diverse technology matrix with three core technologies: computer aided mold design and production, 3D compression molding, and seamless bonding, Regina Miracle is able to develop and produce market-leading products for its long-standing world-renowned brand partners which cover various key sectors comprising intimate wear (including bras, panties, shapewear) and bra pads, sports products (including sports bras, functional sports apparel), consumer electronics components, and footwear, and facilitate cross-sector and cross-category applications.


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

New Media Lab Announces Proposed Listing on The Main Board of SEHK

HONG KONG, Jun 29, 2023 – (ACN Newswire) – New Media Lab Limited ("New Media Lab" or the "Group", Stock Code: 1284.HK), a renowned digital media flagship group in Hong Kong, today announced the details of its share offer (the "Share Offer") and proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").

New Media Lab is offering a total of 150 million new shares under the Share Offer, comprising 135 million placing shares for subscription by investors and 15 million shares for subscription by the public in Hong Kong (the "Allocation"), representing 90% and 10% of the total number of the offer shares, respectively. The Allocation of the offer shares is subject to reallocation, whereby part of the placing shares will be re-allocated to the public offer in case of a certain level of over-subscription in the public offering.

Emperor Corporate Finance Limited and Lego Corporate Finance Limited are the Joint Sponsors of the Group's listing. Emperor Corporate Finance Limited and Lego Securities Limited are the Overall Coordinators. Emperor Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited and Lego Securities Limited are the Joint Coordinators, Joint Bookrunners and Joint Lead Managers. BOCOM International Securities Limited, Guotai Junan Securities (Hong Kong) Limited and Soochow Securities International Brokerage Limited are the Joint Bookrunners and Joint Lead Managers.

The offer price (the "Offer Price") is expected to range between HK$0.84 and HK$0.92 per share. Assuming an Offer Price of HK$0.88 per share, being the mid-point of the indicative Offer Price range, the net proceeds from the Share Offer (after deducting related costs payable for the Share Offer) are estimated to be approximately HK$95.0 million. The net proceeds will be used for (1) expanding and enhancing product lines, as well as data collection and analytical capabilities; (2) mergers and acquisitions and/or strategic alliances with other media or e-commerce market players; (3) constructing in-house media content management platform; (4) general working capital; and (5) repayment of bank borrowings.

The public offer will open on 30 June 2023 (Friday) and close on 5 July 2023 (Wednesday). The allotment results will be announced on 14 July 2023 (Friday). Dealings in the shares of the Group will commence on the Main Board of SEHK on 17 July 2023 (Monday) under the stock code 1284. Shares will be traded in board lots of 5,000 shares each.

New Media Lab is a digital media flagship group, providing one-stop integrated advertising solutions to brand owners and advertising agencies through a number of digital media platforms. The Group has established its online business since 2011, and currently operates nine media brands, including "Weekend Weekly", "Oriental Sunday", "Economic Digest", "New Monday", "More", "GOtrip", "Sunday Kiss", as well as two brands more recently introduced – "SSwagger" and "Madame Figaro". Each brand has its dedicated content pillars covering dining and local attractions, gourmet and gastronomy, fashion and beauty, travel, entertainment news, kids and parenting, electronic gadgets and gaming, finance and investment, as well as designer and luxury labels.

Mr. Royce Lee, Executive Director & Chief Executive Officer of New Media Lab, said, "With our strong digital media presence, we have recorded over 7.4 million and over 1.2 million followers on 10 Facebook's fanpages and 9 Instagram's profiles respectively as of 31 December 2022, both of which are third party social media platforms. Besides, for the year ended 31 December 2022, our 9 websites recorded unique visits of over 219 million. Our engaging contents and effective social media strategy have provided an ideal platform for advertisers, thereby propelling our business."

The Group offers a wide spectrum of advertising products and integrated services on different media platforms to advertisers, including display banners, advertorial and reviews, social platforms newsfeeds, creative and production and strategic services such as SEO and segment marketing, formulating comprehensive and tailor-made advertising solutions. The Group possess a diversified and strong audience base, enabling it to reach and attract different types of audience, and in turn generates value for its advertisers.

For the year end 31 December 2022, the Group's total revenue was HK$240.7 million, in which revenue from the digital advertising accounted for 95.2% of the total revenue; adjusted net profit (excluding listing expenses) was HK$43.6 million. According to the Euromonitor Report, the Group ranked second amongst online advertising companies in Hong Kong in terms of revenue, in three consecutive years between 2020 and 2022, fully reflecting its leadership position in the market.

Looking forward, the Group will (1) pursue growth through mergers and acquisitions and/or strategic alliances with other media or e-commerce market players; (2) further expand product lines and client base and explore opportunities in specific industry verticals such as online finance or banking, in order to cater for diversified needs of different advertisers; (3) strive to enhance data collection and analytical capabilities through the development of e-commerce solution platform to increase the varieties and dimensions of the data that the Group can collect; (4) develop and implement a media content management system to enhance the Group's productivity and unleash its potential; and (5) apply AI and machine learning models in the back-end operations of its platforms to strengthen technological infrastructure, and continue to invest in its technological infrastructure and recruit talent.

Mr. Lee concluded, "We have been engaging in the media business in Hong Kong for more than two decades, and have established an extensive customer network through our early entry into the digital marketing business. The increasing number of younger customers and popularisation of digital platforms as well as the pandemic have led to a significant and rapid change in lifestyle and consumption habits; plus the rapid shift of retailers to utilise online platforms to enhance their sales channels, we are optimistic about the outlook of the online advertising industry. After the completion of the Share Offer, we will actively pursue our expansion strategy and optimise our overall capital structure, in order to capture growth opportunities and enhance our market position."

Offering Details
Number of offer shares: 150,000,000 new shares
Number of placing shares: 135,000,000 new shares
Number of public offer shares: 15,000,000 new shares
Offer Price: HK$0.84 to HK$0.92 per share
Market capitalisation*: HK$504,000,000 to HK$552,000,000
Estimated net proceeds**: HK$95,000,000
Stock code: 1284.HK
*Based on the Offer Price of HK$0.84 and HK$0.92 per share, respectively
**Based on the mid-point of the indicative Offer Price range as HK$0.88 per share

Financial Summary
HK$'000(Audited) For the year ended 31 December
2020 2021 2022
Total revenue 211,589 245,199 240,678
Digital advertising revenue 180,252 231,858 229,169
Adjusted net profit * 41,168 42,405 43,556
Adjusted net profit margin * 19.5% 17.3% 18.1%
* Exclude listing expenses

About New Media Lab Limited
New Media Lab is a digital media flagship group, providing one-stop integrated advertising solutions to brand owners and advertising agencies through a number of digital media platforms. The Group currently operates nine media brands, including "Weekend Weekly", "Oriental Sunday", "Economic Digest", "New Monday", "More", "GOtrip", "Sunday Kiss", as well as two brands recently introduced – "SSwagger" and "Madame Figaro". Each brand has its dedicated content pillars covering dining and local attractions, gourmet and gastronomy, fashion and beauty, travel, entertainment news, kids and parenting, electronic gadgets and gaming, finance and investment, as well as designer and luxury labels. For more information, please visit its website: www.NewMediaLab.com.hk.

Investor/ Financial Media Enquiries
Ms. Anna Luk
Group Investor Relations Director
Emperor Group
Tel: +852 2835 6783
Email: annaluk@emperorgroup.com

Ms. Janice Au
Group Investor Relations Manager
Emperor Group
Tel: +852 2835 6799
Email: janiceau@emperorgroup.com


Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

China Medical System Included in the First ‘Sustainability Yearbook (China)’ of S&P Global

l CMS was included into the first “Sustainability Yearbook (China)” published by S&P Global.

l Nearly 1600 Chinese companies were included in the selection pool, but only 88 companies, including CMS, were finally selected!

SHENZHEN, CHINA, June 29, 2023 – (ACN Newswire) – Recently, S&P Global, the world’s leading corporate sustainability assessment institution, has officially released the first “Sustainability Yearbook 2023 (China)”. China Medical System Holdings Limited (“CMS” or the “Group”), standing out from many outstanding companies, was successfully included in this Yearbook. Previously, S&P Global updated CMS’s Sustainability Score to 53, surpassing 92% of the global peers participating in this evaluation, and it is significantly ahead of the industry average.

S&P Global has published global versions of the “Sustainability Yearbook” for 16 consecutive years, and has received extensive attention and recognition. This year, S&P Global published the “Sustainability Yearbook (China)” for the first time, aiming to identify and recognize Chinese companies that have great sustainable development performance in different industries. Nearly 1600 Chinese companies from 60 industries were included in the selection pool of the yearbook, but only companies that scored within the top 15% of their industries and achieved a S&P Global Sustainability Score within 30% of their industry’s top-performing company can be selected. 88 companies, including CMS, were finally selected into the “Sustainability Yearbook 2023(China)”.

CMS adheres to the concept of sustainable development, and has always paid close attention to the global ESG management trends and outstanding ESG related practices, continued to optimize its internal management, and unceasingly promoted the deep integration of ESG concepts and its operation strategy. In 2022, CMS responded to the Sustainable Development Goals (SDGs) of United Nations, further optimizing the Group’s sustainable development strategy and long-term goals to lead the healthy and sustainable development of CMS.

CMS has always enthusiastically participated in public welfare activities, and actively responded to social needs with practical actions. At the same time, it strives to fulfill its responsibilities and missions of being a corporate citizen in pharmaceutical industry. CMS focuses on unmet clinical needs, and continuously brings differentiated, high-quality, affordable innovative products to patients. In the first half of 2023, three innovative products of CMS were successfully approved for marketing in China, bringing benefits to patients. In the meantime, CMS continues to create a green, clean, friendly and inclusive corporate culture and operating environment through constant improvement of its internal policies, organizational structures and training systems. Looking into the future, CMS will uphold its original aspiration to promote the harmonious development of its operations, the environment and society with long-termism, and to contribute “CMS strength” to the global sustainable development.

About CMS:

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet healthcare needs.

CMS focuses on developing first- or best-in-class innovative products and has made the layout of 30 differentiated pipeline products with strong market potential. CMS deeply engages in specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to strengthen the competitiveness of its cardio-cerebrovascular/gastroenterology business, and independently operated dermatology and medical aesthetic business, and ophthalmology business, whilst enhancing the scale and efficiency. CMS also entered into the Southeast Asian market to create new opportunities to further enhance the sustainable development of the Group.

Media Contact

Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.



Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

33rd Hong Kong Book Fair opens on 19 July

HONG KONG, Jun 29, 2023 – (ACN Newswire) – The 33rd HKTDC Hong Kong Book Fair, organised by the Hong Kong Trade Development Council (HKTDC), will run from 19 to 25 July (Wednesday to Tuesday) at the Hong Kong Convention and Exhibition Centre (HKCEC). With the theme of Children's and Young Adult Literature, the Book Fair will showcase children's and young adults' literature, explore the depth of it and promote the fun of reading in the city, echoing the tagline Reading the World: The Joy of Reading for Children and Youth. This year's Book Fair has invited acclaimed writers and speakers and organised more than 600 seminars and cultural activities. It will run in parallel with the HKTDC Hong Kong Sports and Leisure Expo and HKTDC World of Snacks, altogether attracting about 760 exhibitors, offering visitors three times the enjoyment on a single ticket.


Sophia Chong, Deputy Executive Director of the HKTDC

Edmund Chan, Director of the Hong Kong Publishing Federation; Dr. Elvin Lee, Chairman of the Hong
Kong Publishing Federation; Sophia Chong, Deputy Executive Director of the HKTDC; Yau Lop-poon,
Editor-in-Chief of Yazhou Zhoukan; And this year’s featured writer Wei Ya [L-R]

The two Art Gallery exhibitions at the Book Fair are Featured authors of the theme of the year and
Treasures of Lingnan Culture.


Sophia Chong, Deputy Executive Director of the HKTDC, said: "The theme this year, Children's and Young Adult Literature, selected by the Hong Kong Book Fair Cultural Events Advisory Panel, is particularly thoughtful. Children's and young-adult literature carry profound educational value and play a substantial role in ideation, imagination and formation of world-view of the young. Taking advantage of the theme this year, we wish to pay tribute to Hong Kong children's and young-adult literature writers and promote their works. The HKTDC Hong Kong Sports and Leisure Expo and HKTDC World of Snacks will be held alongside the Book Fair, altogether welcoming about 760 exhibitors from more than 30 countries and regions, with a wide selection of books, cultural art pieces, sports and leisure products and experiences, as well as tasty treats from around the world, making it a summer must-visit spot for Hong Kong citizens."

Art Gallery highlights rich culture of Lingnan

Readers have always liked the Art Gallery which will have two thematic exhibitions this year – Featured writers of the theme of the year and Treasures of Lingnan Culture – at the HKCEC Hall 3 Concourse. The exhibition of featured writers will focus on the selected works and precious collections of the nine writers. They are A Nong, Chau Mat-mat, Wei Ya, Sun Wai-ling, Leong Monk-fung, Poon Ming-chu, Poon Kam-ying, and the late Quenby Fung and Ho Tsz.

They will share their views on the evolution of children's literature and shed light on their writing experiences. Quenby Fung's close friends Dr Justine Woo and Joanne Chan will attend the Book Fair on her behalf while Carmen Ho will join the talk on behalf of her late father Ho Tsz.

The Book Fair, together with the Ling Ngai Art Association, the Hong Kong Calligraphers' Association and other organisations, will jointly launch the Treasures of Lingnan Culture exhibition showcasing calligraphy by famous artists, paintings from the Lingnan school and intangible cultural heritage – Canton Porcelain – to help promote the unique artistic heritage of Lingnan.

Wong Fei-hung is considered the guru of Lingnan culture. The Book Fair has dedicated an exhibition to honour his legacy by featuring books, martial arts magazines, movie programme booklets and stage photos related to his movies in the 1950s and 1960s, among other invaluable items, helping visitors visualise the history of Lingnan martial arts and culture. The Art Gallery will incorporate interactive design and display, bringing to life Lingnan customs and traditions.

Brand-new World of Art & Culture to facilitate cultural exchange

Sponsored by Create Hong Kong* (CreateHK) of the Government of the Hong Kong Special Administrative Region (HKSAR), the World of Art & Culture zone will be launched to further strengthen Hong Kong's position as an East-meets-West centre for international cultural exchange. Curated by renowned Hong Kong designers, the zone vividly depicts literature and cultural arts related to the youth-focused theme from 24 countries and regions including France, Hungary, Switzerland, Spain, Korea, Brunei and more. The zone will also exhibit the awarded books under Children & Youth and Art & Design categories of Hong Kong Publishing Biennial Award 2023. There will be workshops where participants experience art, culture and creativity to help readers develop a deeper understanding of different cultures.

Brightest minds share tips on creative insights at Eight Seminar Series

The Eight Seminar Series continues to be a Book Fair highlight. The seminars include: Theme of the year, Renowned Writers, English and International Reading, World of Knowledge, Children and Youth Reading, Personal Development and Spiritual Growth, Lifestyle and Hong Kong Cultural and Historical. Partnering with Ming Pao and Yazhou Zhoukan, the HKTDC again organises the Renowned Writers Seminar Series addressed bv leading Chinese-language authors as speakers. Speakers include Yu Hua, considered one of the three most talented writers in China; Luo Zhen-yu, a motivational speaker with an online and offline audience of over 10 million for his New Year's Eve speech; Ma Boyong, famous novelist; Xu Zhi-yuan, founder of the bookstore Owspace; Pang Bei, a Mao Dun literature prize winner; Chen Chun-cheng, a Blancpain-Imaginist literary prize winner, Guan Zhong-min, famous Taiwanese host; Shum Sai-shing, scholar of Hong Kong history; Brian Wong, Balliol College Rhodes scholar and Susana Cheung Chui-yung, a veteran journalist. They will share ups and downs of their writing journey with Hong Kong booklovers.

The Book Fair is privileged to draw high-profile English-language writers to host seminars for the English and International Reading Seminar Series. The special guests include Indonesian writer Jesse Q Sutanto, who won the 2021 Comedy Women in Print Prize; Theadora Whittington, a well-known British children's book author who published The Sand Turtle; Jane Houng, a British children's literature author who has been living in Hong Kong for more than 30 years; Winston Chu, Vice President of Society for Protection of the Harbour; Libby Lam, aka Lady Libby, children's book author; and Mark O'Neill, an experienced researcher of Chinese history. Speakers of other series include Hong Kong pop band The Wynners formed in the 70s, former Hong Kong cycling team member Wong Kam-po, Executive Council convener Regina Ip and artiste Priscilla Wong. A broad spectrum of topics will be covered.

The Book Fair continues to invite many outstanding figures to share their stories with children at the Storytelling by Celebrities session. The speakers include Hong Kong education expert Dr Chan Wai-kai; orthopaedic surgeon Dr Liyeung Lucci Lugee; CEO of Chinese Estates Holdings Limited Chan Hoi-wan; Chairman of Board of Trustees of Wai Yin Association Mandy Cho, Chairman of Shininglife Charity Jade Kwan; artiste Coco Chiang and more. (For more details on the seminars and the lineup of speakers, please visit: https://hkbookfair.hktdc.com/en/Events/Event-Schedule.html)

Fun-filled Sports and Leisure Expo promotes wellness

The Hong Kong Sports and Leisure Expo features eight thematic zones – Sports Hub, Outdoor Adventure, Health & Fitness, Fun & Learn, Board Games, Photography World, Japan Pavilion and Handicraft Market. Hong Kong triathlete Cheri Cho and Hong Kong break-dancer B-girl Lady Little Chan Ka-yi will talk about their journey as athletes and perform on stage.

The Sports Hub zone offers visitors fun activities free of charge, including a 4-metre-high mobile rope net, interactive boxing sandbags and a VR rowing boats experience brought by the Hong Kong Playground Association for its 90th anniversary this year; the racing sports experience and a 1:1 "Golden Sixty" Horse Sculpture presented by the Hong Kong Jockey Club; the skateboarding trial classes and demonstrations provided by the Seeds Skateboarding Institution (SeedSkate) and more. Hong Kong athletes have notched up great achievements recently, the Hong Kong Sports Institute will display gear and supplies used by Olympic medallists Edgar Cheung, Siobhan Haughey and Sarah Lee during competitions and trainings. The exhibition area of Board Games has nearly doubled this year. People On Board will present a variety of Hong Kong-themed board games crossover with MTR, HKMA and Lee Kum Kee.

The Japan National Tourism Organization (JNTO) and 14 Japanese prefectures and cities have teamed up to form a Japan Pavilion showcasing the country's attractions and cultural characteristics. Every August, Aomori Prefecture of Japan holds the renowned Aomori Nebuta ("Sleeping Devil") Festival with Nebuta lanterns parading around the centre of the Prefecture. To mark its debut participation this year, a 2-metre Nebuta lantern will be set up, allowing visitors to appreciate the majestic Nebuta up close, and to feel the festive atmosphere. The Japan Pavilion will also bring in traditional dances and mascot performances from various prefectures and cities.

World of Snacks offers delicacies from around the world

The World of Snacks features six thematic zones – Travel Delights, Chocolate and Sweet Factory, Oldie Snacks, Yummy & Healthy, Party Time and Snack Bar – assembling more than 1,200 popular treats from across the globe. There are also workshops and activities on-site, including tasting sessions, hand-brewed coffee with Zen concept combined with meditation experience.

'Cultural July' nurtures a cultural oasis

Alongside the Book Fair, the HKTDC collaborates with the Leisure and Cultural Services Department (LCSD), publishers, educational and cultural institutions, malls and cafes to organise cultural events across 18 districts of Hong Kong from 16 June to 31 July, as part of the citywide Cultural July campaign. These include writing workshops, seminars by renowned writers and book launches where readers gain insight into the journey and fun of writing.

The Cultural Journey Online will continue to be available on the Book Fair website gathering e-reading resources and activities like virtual seminars and exhibitions from our partners which include: SHKP Reading Club's Read For More, Hong Kong Public libraries, Culture is…, Google Arts & Culture, encouraging citizens to expand their horizons and promoting a reading culture.

To ensure an even flow of visitors throughout the day, the HKTDC offers morning admission tickets and a special re-entry promotion. Additionally, new online ticketing channels via AlipayHK and the Alipay App are available. No physical ticket sales will be arranged at the fairground, visitors can pay with AlipayHK App, Alipay App or Octopus cards at the entrance's toll booths. More details of the ticketing arrangements can be found below.
* Disclaimer: The Government of the Hong Kong Special Administrative Region provides funding support to the project only, and does not otherwise take part in the project. Any opinions, findings, conclusions or recommendations expressed in these materials/events (or by members of the project team) are those of the project organisers only and do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Culture, Sports and Tourism Bureau, Create Hong Kong, the CreateSmart Initiative Secretariat or the CreateSmart Initiative Vetting Committee.

Websites:
– Hong Kong Book Fair website: www.hkbookfair.com
– Hong Kong Sports and Leisure Expo website https://www.hktdc.com/event/hksportsleisureexpo/en
– World of Snacks website https://www.hktdc.com/event/worldofsnacks/en
– HKTDC Media Room: http://mediaroom.hktdc.com
– Photo Download: https://bit.ly/3XtHJh0
– Photos of the exhibits, key speakers and other Book Fair highlights can be found at: https://bit.ly/43YvlYO

About HKTDC

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on Twitter @hktdc and LinkedIn

Media enquiries
Should members of the press have any enquiries, please contact:

Hong Kong Book Fair
Yuan Tung Financial Relations:
Anson Wong, Tel: +852 3428 3413, Email: awong@yuantung.com.hk
Salina Cheng, Tel: +852 3428 5691, Email: salcheng@yuantung.com.hk
Agnes Yiu, Tel: +852 3428 5690, Email: ayiu@yuantung.com.hk

HKTDC's Communications & Public Affairs Department:
Katy Wong, Tel: +852 2584 4524, Email: katy.ky.wong@hktdc.org
Sunny Ng, Tel: +852 2584 4357, Email: sunny.sl.ng@hktdc.org

Hong Kong Sports and Leisure Expo, World of Snacks
HKTDC's Communications & Public Affairs Department:
Katy Chan, Tel: +852 2584 4239, Email: kate.hy.chan@hktdc.org

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Soligenix, Inc. CEO is Featured in an Interview with SmallCaps Daily

NEW YORK, Jun 29, 2023 – (ACN Newswire) – Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is excited to announce its CEO, President, and Chairman, Christopher J. Schaber, recently conducted an interview with SmallCaps Daily, providing in-depth insights into the Company's recent achievements, including the positive results from the compatibility study of HyBryte(TM) in the treatment of cutaneous T-cell lymphoma (CTCL), upcoming milestones, and unwavering commitment to addressing critical unmet medical needs in the rare disease landscape.



To read the full interview visit: https://smallcapsdaily.com/soligenix-inc-ceo-sits-down-with-smallcaps-daily/

About Soligenix, Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203).

Our Public Health Solutions business segment includes active development programs for RiVax(R), our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com

Contact Information
SmallCapsDaily
info@smallcapsdaily.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Solar Powered Sunscreen: EcoZinc a World First in Sustainable Zinc Oxide Innovation

BRISBANE, AUS, Jun 29, 2023 – (ACN Newswire) – Advance ZincTek, Australia's leading manufacturer of natural Sunscreen Actives, announces the launch of EcoZinc, the world's first solar-powered, non-nano zinc oxide powder for SPF-rated cosmetics and sunscreens. EcoZinc not only minimizes environmental impact, but also achieves a dramatic reduction in carbon emissions-saving over 1011g of CO2 per kilowatt of energy used compared to traditional zinc oxide production.


Solar Installation


Engineered via Advance ZincTek's state-of-the-art ZinClear XP architecture, it ensures unmatched sustainability & uniform particle distribution in five BET ranges. Offering 23.08% more absorbance at a wavelength of 290nm than some competitors, EcoZinc merges top-tier skin protection and sustainability.

"EcoZinc represents a major evolution for both skincare brands and consumers striving to protect their skin and the planet," said Advance ZincTek's Managing Director Geoff Acton. "Our 100% solar-powered manufacturing process testifies to our resolution to spearhead the industry transition towards safer, sustainable sun protection."

EcoZinc's eco-friendly zinc oxide provides an integral solution for reef-safe cosmetics that meet the stringent regulations of regions such as Hawaii, Mexico, and Thailand. Through EcoZinc, companies can eliminate harmful synthetic chemicals from their products, significantly minimizing the impact on marine life.

Advance ZincTek's recent announcement on June 21, 2023, revealed a significant Australian sunscreen manufacturer's commitment to transition to EcoZinc for all their products, indicating a marked shift in industry preference towards safer, sustainable sunscreen ingredients.

Joseph Mizikovsky, product lead for Reef Safe, a new brand leveraging EcoZinc in its formulations, noted the industry's necessity for such a shift. "We're thrilled to be part of the sustainable innovation that EcoZinc brings. Numerous sunscreen brands, including many renowned Australian labels, typically rely on chemical UV filters; however, none have been deemed safe and effective by the US FDA (Food and Drug Administration). With EcoZinc, we aim to establish a new standard, prioritizing safety and sustainability to minimize environmental impact, especially in sensitive areas like marine parks and reefs. Zinc oxide remains the only broad spectrum UV filter approved as safe and effective by the FDA," stated Mizikovsky.

Reef Safe's incorporation of EcoZinc into their sunscreen signifies not just the delivery of a product that meets the highest global sustainability and safety standards but also endorses the global shift towards clean, green, and safe sun care solutions.

Fulfilling Environment, Social, and Governance (ESG) commitments, EcoZinc provides benefits that directly aid corporate ESG adherence, thereby enabling companies to achieve their sustainability goals while delivering exceptional products.

For more information and to request a sample for your brand, visit https://www.advancezinctek.com/ecozinc.

Contact Information:
Geoff Acton
Managing Director
sales@antaria.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun

SHELTON, CT, Jun 29, 2023 – (ACN Newswire) – NanoViricides, Inc. (NYSE American:NNVC) (the "Company") reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17, 2023 with two oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies.

"We believe that the start of the Phase 1a/1b safety and efficacy clinical trial is an important milestone not only for NanoViricides and Karveer Meditech, India, but for the whole world," said Dr. Anil Diwan, Ph.D., President and Executive Chairman of the Company, explaining, "NV-CoV-2 is aimed at satisfying the as-yet-unmet medical need for a highly effective broad-spectrum, pan-coronavirus drug that can be used for all patient populations. Further, we believe the nanoviricides technology adds a valuable tool to the basket of worldwide preparedness and response strategies for future viral pandemics."

The Company is a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, called "nanoviricides". NV-CoV-2, the Company's lead drug candidate for the treatment of coronavirus infections including COVID and potentially many cases of long COVID, has now entered Phase 1a/1b human clinical trials that are sponsored by Karveer Meditech Pvt. Ltd. India, the Company's Licensee and co-developer in India (see below).

The Clinical Trial Will Evaluate Both Safety and Initial Efficacy Indications in COVID patients:

Phase 1a will assess the safety and tolerability of a new molecule (drug product NV-CoV-2 containing API NV-387) in healthy subjects. In Phase 1b, patients with mild to moderate COVID-19 will be enrolled to assess indication of efficacy.

The Single Dosing of Healthy Volunteers portion of the Phase 1a began with the dosing of a first set of volunteers on June 17, 2023. This set of volunteers was successfully discharged after a 48 hours in-hospital stay for observation, and will be further assessed in a final out-person visit as per the protocol. Further recruitments and dosings are scheduled as per the protocol.

NV-387 Is a First-in-Class Chemical Nanomachine that Acts by a Novel Mechanism of Action:

The Company calls the antiviral mechanism of NV-387 "Re-Infection Blocker." The drug is designed to directly attack the virus particle with a multi-pronged attack and thereby disable the virus completely so that it cannot further infect human cells and the infection cannot progress. The Company believes that this novel antiviral mechanism can become an important new tool for worldwide pandemic preparedness and response strategies to combat future viral pandemics.

NV-387 has demonstrated strong pan-coronavirus effectiveness as well as excellent safety in pre-clinical studies. Both our oral drug products: (i) NV-CoV-2 Oral Syrup, and (ii) NV-CoV-2 Oral Gummies are formulations of the same active pharmaceutical ingredient (API), NV-387.

The Team Behind the Clinical Trials:

The Company previously announced that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India ("Karveer"). Under this Agreement, Karveer has the right to commercialize the Company's COVID drugs, NV-CoV-2 and NV-CoV-2-R, in India. To enable commercialization, Karveer has undertaken Clinical Development and Evaluation and is sponsoring these two drugs in India for this purpose.

Karveer Meditech has retained the Clinical Trials Organization, PristynCR Solutions, Pvt. Ltd., Aurangabad, Maharashtra, India, to develop and prosecute the clinical trials applications and conduct the clinical trials.

The Phase 1a/1b clinical trial labeled KM-NVCoV2-001 is being conducted at a single site, Clinical Research Unit in the Department of Clinical Pharmacology, Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India.

The clinical trial protocol and information can be found in India's official clinical trials registry, https://ctri.nic.in/Clinicaltrials/pubview.php by entering the sponsor's name "Karveer Meditech" and selecting the search criterion "Sponsor."

About Mahatma Gandhi Mission's Medical College and Hospital, Aurangabad, India

Mahatma Gandhi Mission's Medical College and Hospital is a private, "NABH accredited" medical college hospital (A++ grade). The hospital has 700 beds, including 85 beds of Intensive care units. The hospital provides health care services through various charity schemes that enable free healthcare services to the eligible public. Additionally, the hospital also provides fee-paid specialty services and medical care. The hospital provides medical and surgical services along with super-speciality services such as Cardiology, Nephrology, Plastic Surgery, Neurosurgery, and Urology.

The hospital is well-supported with state of the art diagnostic laboratories which includes a NABL accredited Central Pathology Laboratory, Radiology and other services.

The hospital treats over 4,000 patients including out-patients and in-patients daily. The hospital has treated well over 20,000 mild, another 20,000+ moderate, and at least 12,000+ severe cases of COVID-19.

The Clinical Trial Unit at the Hospital has conducted multiple clinical trials for COVID drugs in different clinical phases.

About PristynCR Solutions Pvt. Ltd.

PristynCR Solutions Pvt. Ltd. is a contract research organization helping global enterprises to advance their regulatory and clinical research. Apart from Pharmaceutical trials services PristynCR also provides Medical Writing, Data Management, Pharmacovigilance and Regulatory Insight services; in short, a full-service stack from drug discovery to approval including tech transfer requirements.

About Karveer Meditech Private Limited

Karveer Meditech Private Limited is a small and aspiring dynamic pharmaceutical company in India. It has developed and commercialized in local markets more than a dozen different generic and semi-branded pharmaceutical drugs as well as Ayurvedic medicines and vitaminized nutritional supplement protein powder products. It was co-founded by Dr. Anil Diwan, who serves as a Director and is a passive investor. Dr. Diwan is also co-founder of and President and Chairman of the Board of NanoViricides. Karveer Meditech is independently managed by its Managing Director in India.

About NanoViricides

NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-CoV-2 for the treatment of COVID caused by SARS-CoV-2 coronavirus. Our other advanced candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project exact dates for the regulatory activities in progressing its drug candidates because of the Company's significant dependence on external collaborators and consultants. The Company is currently focused on advancing NV-CoV-2 through Phase I/II human clinical trials.

NV-CoV-2 is the Company's nanoviricide drug candidate for COVID. NV-CoV-2-R is another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing a broad pipeline of drugs against a number of viruses, with preclinical safety and effectiveness successes achieved already in many cases. NanoViricides' platform technology and programs are based on the TheraCour(R) nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses, enteroviruses, and other viruses that it engages into research for, if the initial research is successful. TheraCour has not denied any licenses requested by the Company to date. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Disclosure Statement

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and that could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. In particular, as is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety in human clinical trials to lead to a successful pharmaceutical product, including our coronavirus drug development program.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
MJ Clyburn
TraDigital IR
clyburn@tradigitalir.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com